Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, CT.
Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC.
Am Heart J. 2022 Mar;245:136-148. doi: 10.1016/j.ahj.2021.12.004. Epub 2021 Dec 23.
Clinicians vary widely in their preferred diagnostic approach to patients with non-acute chest pain. Such variation exposes patients to potentially avoidable risks, as well as inefficient care with increased costs and unresolved patient concerns.
The Prospective Randomized Trial of the Optimal Evaluation of Cardiac Symptoms and Revascularization (PRECISE) trial (NCT03702244) compares an investigational "precision" diagnostic strategy to a usual care diagnostic strategy in participants with stable chest pain and suspected coronary artery disease (CAD).
PRECISE randomized 2103 participants with stable chest pain and a clinical recommendation for testing for suspected CAD at 68 outpatient international sites. The investigational precision evaluation strategy started with a pre-test risk assessment using the PROMISE Minimal Risk Tool. Those at lowest risk were assigned to deferred testing (no immediate testing), and the remainder received coronary computed tomographic angiography (cCTA) with selective fractional flow reserve (FFR) for any stenosis meeting a threshold of ≥30% and <90%. For participants randomized to usual care, the clinical care team selected the initial noninvasive or invasive test (diagnostic angiography) according to customary practice. The use of cCTA as the initial diagnostic strategy was proscribed by protocol for the usual care strategy. The primary endpoint is time to a composite of major adverse cardiac events (MACE: all-cause death or non-fatal myocardial infarction) or invasive cardiac catheterization without obstructive CAD at 1 year. Secondary endpoints include health care costs and quality of life.
PRECISE will determine whether a precision approach comprising a strategically deployed combination of risk-based deferred testing and cCTA with selective FFR improves the clinical outcomes and efficiency of the diagnostic evaluation of stable chest pain over usual care.
临床医生在处理非急性胸痛患者时,其首选的诊断方法差异很大。这种差异使患者面临潜在的可避免风险,以及效率低下的治疗,导致成本增加和患者的问题仍未解决。
前瞻性随机试验最优评估心脏症状和血运重建(PRECISE)试验(NCT03702244)比较了一种研究性的“精准”诊断策略与常规护理诊断策略,用于稳定型胸痛和疑似冠心病(CAD)的参与者。
PRECISE 试验在 68 个国际门诊站点随机纳入了 2103 名稳定型胸痛且临床推荐进行疑似 CAD 检测的参与者。研究性的精准评估策略首先使用 PROMISE 最小风险工具进行预测试风险评估。那些风险最低的患者被分配进行延迟检测(不立即检测),其余患者则接受冠状动脉计算机断层扫描血管造影(cCTA),对于任何狭窄程度≥30%且<90%的患者进行选择性血流储备分数(FFR)检测。对于随机分配到常规护理组的参与者,临床护理团队根据常规做法选择初始的非侵入性或侵入性检测(诊断性血管造影)。常规护理策略中禁止使用 cCTA 作为初始诊断策略。主要终点是 1 年内主要不良心脏事件(MACE:全因死亡或非致死性心肌梗死)或无阻塞性 CAD 的侵入性心脏导管插入术复合终点的时间。次要终点包括医疗保健成本和生活质量。
PRECISE 将确定一种精准方法是否可以改善稳定型胸痛的诊断评估的临床结果和效率,该方法包括基于风险的延迟检测和选择性 cCTA 与选择性 FFR 的策略性部署组合,优于常规护理。